- Home
- EDD vs GOSS Comparison
EDD vs GOSS Comparison
Compare EDD & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDD
- GOSS
- Stock Information
- Founded
- EDD 2007
- GOSS 2015
- Country
- EDD United States
- GOSS United States
- Employees
- EDD N/A
- GOSS N/A
- Industry
- EDD Finance Companies
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- EDD Finance
- GOSS Health Care
- Exchange
- EDD Nasdaq
- GOSS Nasdaq
- Market Cap
- EDD 329.4M
- GOSS 347.8M
- IPO Year
- EDD N/A
- GOSS 2019
- Fundamental
- Price
- EDD $5.30
- GOSS $2.47
- Analyst Decision
- EDD
- GOSS Strong Buy
- Analyst Count
- EDD 0
- GOSS 4
- Target Price
- EDD N/A
- GOSS $8.50
- AVG Volume (30 Days)
- EDD 254.3K
- GOSS 3.1M
- Earning Date
- EDD 01-01-0001
- GOSS 08-05-2025
- Dividend Yield
- EDD 7.52%
- GOSS N/A
- EPS Growth
- EDD N/A
- GOSS N/A
- EPS
- EDD N/A
- GOSS N/A
- Revenue
- EDD N/A
- GOSS $40,237,000.00
- Revenue This Year
- EDD N/A
- GOSS N/A
- Revenue Next Year
- EDD N/A
- GOSS $30.65
- P/E Ratio
- EDD N/A
- GOSS N/A
- Revenue Growth
- EDD N/A
- GOSS N/A
- 52 Week Low
- EDD $4.22
- GOSS $0.66
- 52 Week High
- EDD $4.95
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- EDD 56.10
- GOSS 68.08
- Support Level
- EDD $5.24
- GOSS $2.38
- Resistance Level
- EDD $5.42
- GOSS $2.65
- Average True Range (ATR)
- EDD 0.05
- GOSS 0.15
- MACD
- EDD -0.01
- GOSS 0.03
- Stochastic Oscillator
- EDD 40.00
- GOSS 76.67
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.